Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTE: Atorvastatin in intermediate coronary artery disease
NCT01946815Phase 3Completed
- Start
- Sep 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin in coronary artery disease (CAD). Primary endpoint: Change in Fractional Flow Reserve at 12 months. Started Sep 2013; status: completed.
02
Drugs
atorvastatin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01946815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946815.